secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0001104659-24-106432
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron expects $56M pre-tax IPR&D charge in Q3 2024, reducing EPS by $0.43
-----------------------------------------------------------------------------

- Preliminary $56M pre-tax acquired IPR&D charge expected for Q3 2024 from milestone/up-front payments.
- GAAP and non-GAAP diluted EPS expected to be negatively impacted by approximately $0.43.
- Charge relates to collaboration and licensing agreement payments; such charges are not forecast.
- Q3 2024 financial results are not finalized and subject to closing procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465924106432/0001104659-24-106432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465924106432/tm2419098d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-106432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer